NASDAQ: TRAW
Traws Pharma, Inc.CIK 0001130598 · SIC 2834 · Pharmaceutical Preparations
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (HPQ 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade TRAW commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Traws Pharma launches antiviral program targeting Hantavirus and Ebola outbreaks
2 material changes detected. Sign up free to read the summary.
Traws Pharma updates ATM offering limit to $3.1M under baby shelf rules
3 material changes detected. Sign up free to read the summary.
Summary not yet generated.
Traws Pharma reports Q1 2026 financial results in Regulation FD disclosure
2 material changes detected. Sign up free to read the summary.
net income -$7.1M. Traws remedies control weaknesses, raises as FDA halts lead drug; cash
5 material changes detected. Sign up free to read the summary.
revenue $2.8M, net income $9.2M. Traws reports going-concern warning, Symbio termination, and Phase 2 COVID data
5 material changes detected. Sign up free to read the summary.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Aug 14, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Condensed Consolidated Statements of Operations (Unaudited)
| Description | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Revenue | — | 2,733,000 | — | 2,790,000 |
| Operating expenses: | ||||
| Research and development | 1,101,000 | 2,291,000 | 6,013,000 | 4,797,000 |
| General and administrative | 3,479,000 | 1,691,000 | 5,513,000 | 4,445,000 |
| Other operating income | (1,405,000) | — | (1,405,000) | — |
| Total operating expenses | 3,175,000 | 3,982,000 | 10,121,000 | 9,242,000 |
| Loss from operations | (3,175,000) | (1,249,000) | (10,121,000) | (6,452,000) |
| Change in fair value of warrant liability | 215,000 | 146,000 | 56,000 | 26,659,000 |
| Other (loss) income, net | (94,000) | 188,000 | (96,000) | 368,000 |
| Net (loss) income | (3,054,000) | (915,000) | (10,161,000) | 20,575,000 |
| Net (loss) income attributable to common stockholders, basic and diluted | (2,611,000) | (625,000) | (8,446,000) | 14,860,000 |
| Weighted-average shares of common stock outstanding, basic | 15,864,041 | 5,820,903 | 13,266,763 | 7,359,825 |
| Net (loss) income per share of common stock, basic | (0.16) | (0.11) | (0.64) | 2.02 |
| Weighted-average shares of common stock outstanding, diluted | 15,864,041 | 5,820,903 | 13,266,763 | 7,614,325 |
| Net (loss) income per share of common stock, diluted | (0.16) | (0.11) | (0.64) | 1.95 |
| Net (loss) income attributable to Series C Preferred stockholders, basic and diluted | (443,000) | (290,000) | (1,715,000) | 5,715,000 |
| Weighted-average shares of Series C Preferred outstanding, basic and diluted | 6,737 | 6,759 | 6,737 | 7,077 |
| Net (loss) income per share of Series C Preferred, basic and diluted | (65.76) | (42.91) | (254.56) | 807.55 |
Condensed Consolidated Balance Sheets (Unaudited)
| Description | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | 5,016,000 | 3,820,000 |
| Tax incentive and other receivables | 3,454,000 | 3,794,000 |
| Prepaid expenses and other assets | 553,000 | 365,000 |
| Total current assets | 9,023,000 | 7,979,000 |
| Property and equipment, net | 5,000 | 7,000 |
| Intangible assets, net | 2,441,000 | 2,527,000 |
| Other assets | 1,000 | 104,000 |
| Total assets | 11,470,000 | 10,617,000 |
| Liabilities and stockholders’ equity (deficit) | ||
| Current liabilities: | ||
| Accounts payable | 6,334,000 | 5,653,000 |
| Accrued expenses and other liabilities | 3,401,000 | 5,493,000 |
| Total current liabilities | 9,735,000 | 11,146,000 |
| Warrant liabilities | 44,000 | 100,000 |
| Total liabilities | 9,779,000 | 11,246,000 |
| Commitments and contingencies (Note 5) | ||
| Stockholders’ deficit: | ||
| Series C Preferred stock, $0.01 par value, 5,000,000 shares authorized, 7,440 shares issued and 6,737 shares outstanding at June 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.01 par value, 250,000,000 shares authorized, 15,264,812 and 9,067,774 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 152,000 | 90,000 |
| Additional paid-in capital | 651,689,000 | 639,259,000 |
| Accumulated deficit | (650,145,000) | (639,984,000) |
| Accumulated other comprehensive (loss) income | (5,000) | 6,000 |
| Total stockholders’ equity (deficit) | 1,691,000 | (629,000) |
| Total liabilities and stockholders’ equity (deficit) | 11,470,000 | 10,617,000 |
Condensed Consolidated Statements of Cash Flows (Unaudited)
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Operating activities: | ||
| Net (loss) income | (10,161,000) | 20,575,000 |
| Adjustment to reconcile net (loss) income to net cash used in operating activities: | ||
| Change in fair value of warrant liability | (56,000) | (26,659,000) |
| Depreciation and amortization | 88,000 | 2,000 |
| Stock-based compensation | 1,450,000 | 266,000 |
| Changes in assets and liabilities: | ||
| Receivables | 340,000 | 442,000 |
| Prepaid expenses and other current assets | (188,000) | 882,000 |
| Other assets | 5,000 | — |
| Accounts payable | 534,000 | (3,605,000) |
| Accrued expenses and other current liabilities | (2,092,000) | (528,000) |
| Deferred revenue | — | (2,791,000) |
| Net cash used in operating activities | (10,080,000) | (11,416,000) |
| Financing activities: | ||
| Proceeds from sale of common stock pursuant to the ATM | 2,017,000 | 3,379,000 |
| Proceeds from sale of common stock pursuant to the April Offering | 10,000,000 | — |
| Payment of offering costs | (730,000) | (287,000) |
| Proceeds from exercised prefunded warrants | — | 16,000 |
| Net cash provided by financing activities | 11,287,000 | 3,108,000 |
| Effect of foreign currency translation on cash | (11,000) | 51,000 |
| Net increase (decrease) in cash and cash equivalents | 1,196,000 | (8,257,000) |
| Cash and cash equivalents at beginning of period | 3,820,000 | 21,338,000 |
| Cash and cash equivalents at end of period | 5,016,000 | 13,081,000 |
| Supplemental disclosure of cash flow information: | ||
| Deferred offering costs in accounts payable | 147,000 | 178,000 |
| Reclassification of warrant liability upon exercise of prefunded warrants and amended warrant agreements | — | 15,827,000 |
Amounts as printed on the EDGAR/iXBRL face. Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗